Hiroshi Ishihara

This inventor holds 9 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Eisai R&d Management Co., Ltd., Mercian Corporation. Active years: 2008-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroshi Ishihara. Retrieved from https://idiyas.com/inventor/hiroshi-ishihara-ljyyts4w

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 9

% Patents Active = 55.6

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 11(Granted Patents)

Location History:

Ibaraki, JP (2010)
Tsukuba, JP (2008 - 2024)

Company Filing History:

9 out of 530

Eisai R&d Management Co., Ltd.

where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12042560 - Liposome composition (2024-07-23),

2. 11071713 - Liposome composition (2021-07-27),

3. 10765633 - Formulation comprising liposomes (2020-09-08),

4. 9968583 - Method of manufacture of liposome composition (2018-05-15),

5. 7790887 - Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same (2010-09-07),

6. 7767812 - Crystals of pyrimidine compound and process for producing the same (2010-08-03),

7. 7718807 - Salt of 1,2-dihydropyridine compound (2010-05-18),

8. 7655442 - Method for stabilizing macrolide compounds (2010-02-02),

9. 7396928 - Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same (2008-07-08),

Title: Innovations of Hiroshi Ishihara: A Profile of an Influential Inventor

Introduction

Hiroshi Ishihara is a notable inventor based in Tsukuba, Japan, known for his contributions to the field of pharmaceutical innovations. With a total of nine patents to his name, he has developed significant advancements, particularly in liposome compositions that enhance the efficacy of therapeutic agents, such as eribulin.

Latest Patents

Among his recent innovations, Hiroshi Ishihara's latest patents focus on novel liposome compositions that incorporate eribulin or its pharmacologically permissible salts. These compositions not only demonstrate improved delivery mechanisms but also show promise in enhancing the drug's pharmacological properties. The methods of manufacture associated with these liposome formulations have potential implications in cancer treatment, showcasing the innovative approaches Ishihara has contributed to the pharmaceutical field.

Career Highlights

Throughout his career, Hiroshi Ishihara has worked with prominent companies that have laid the groundwork for his inventive insights. Noteworthy among these is Eisai R&D Management Co., Ltd., a leading pharmaceutical company renowned for its commitment to research in oncology and other therapeutic areas. Another key organization he collaborated with is Mercian Corporation, which has played a vital role in his developmental projects.

Collaborations

Hiroshi Ishihara has been fortunate to work alongside esteemed colleagues such as Hiroshi Kikuchi and Kenji Hyodo. Their collaborative efforts have significantly contributed to advancing research and innovations in the realm of drug delivery systems.

Conclusion

Hiroshi Ishihara's inventive journey highlights his dedication to enhancing pharmaceutical compositions through innovative technologies. With his ongoing work and a strong foundation of patents, he continues to influence the landscape of drug development, exemplifying the vital role that inventors play in advancing healthcare solutions.

Profile summary based on public USPTO records.